A new reality in genetic medicine lies ahead, one that will be ushered in with the advent of safe, effective, and redosable nucleic acid delivery technologies. At Entos, we develop next generation genetic medicines using our proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system. Fusogenix PLVs are formulated with FAST proteins toenable the delivery of nucleic acid into target cells through direct fusion. For more information, visit www.entospharma.com, or follow Entos on Twitter or LinkedIn.

Biotechnology

Health Care

Life Sciences

Pharmaceutical

Entos Pharmaceuticals

John Lewis

Steve C.

Kimberly B. Henshaw

Jailal Ablack

Jason Ding, FCPA, FCA

DeEtte Mack

Arun Raturi

Scientific Research and Development

Leadership Team

Operations Team

Teams at Entos Pharmaceuticals

Scientific Research and Development

Leadership Team

Operations Team